Abstract
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), sometimes referred to as the novel coronavirus (2019-nCoV), is currently a worldwide threat to public health. According to the Johns Hopkins University monitor (available at, coronavirus.jhu.edu/map), there have been more than 10 million reported cases of coronavirus 2019 disease (COVID-19) and 500,000 deaths as of June 29, 2020, deeming urgent the identification of a drug candidate and treatment regimen.
Objective: This work aims to compile the current knowledge available on this drug, including its background, approved uses, some synthetic methods, the primary pharmacological aspects, the results against COVID-19 reported so far, and ongoing clinical trials against COVID-19.
Methods: We reviewed relevant press releases, scientific articles, and official documents to compile information about Favipiravir.
Results: We highlight, in a clear and concise form, not only the published and ongoing clinical trials on the use of Favipiravir against COVID-19 but also compile some relevant synthetic and pharmacological information available about this drug.
Conclusion: The Antiviral Favipiravir has shown interesting preliminary results, but it seems too early to recommend a treatment protocol for COVID-19 based on this drug. Robust clinical trials that will provide less biased data on its efficacy and safety are being pushed forward by FUJIFILM Corporation and by research groups around the globe.
Keywords: Coronavirus, COVID-19, favipiravir, synthesis, mechanism of action, pharmacology
Coronaviruses
Title:Favipiravir in the Spotlight: In Search of Treatment Against COVID-19
Volume: 2 Issue: 1
Author(s): Victor Facchinetti and Marcus Vinícius Nora de Souza*
Affiliation:
- Fundacao Oswaldo Cruz, Instituto de Tecnologia em Farmacos, Rua Sizenando Nabuco 100, Rio de Janeiro, RJ,Brazil
Keywords: Coronavirus, COVID-19, favipiravir, synthesis, mechanism of action, pharmacology
Abstract:
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), sometimes referred to as the novel coronavirus (2019-nCoV), is currently a worldwide threat to public health. According to the Johns Hopkins University monitor (available at, coronavirus.jhu.edu/map), there have been more than 10 million reported cases of coronavirus 2019 disease (COVID-19) and 500,000 deaths as of June 29, 2020, deeming urgent the identification of a drug candidate and treatment regimen.
Objective: This work aims to compile the current knowledge available on this drug, including its background, approved uses, some synthetic methods, the primary pharmacological aspects, the results against COVID-19 reported so far, and ongoing clinical trials against COVID-19.
Methods: We reviewed relevant press releases, scientific articles, and official documents to compile information about Favipiravir.
Results: We highlight, in a clear and concise form, not only the published and ongoing clinical trials on the use of Favipiravir against COVID-19 but also compile some relevant synthetic and pharmacological information available about this drug.
Conclusion: The Antiviral Favipiravir has shown interesting preliminary results, but it seems too early to recommend a treatment protocol for COVID-19 based on this drug. Robust clinical trials that will provide less biased data on its efficacy and safety are being pushed forward by FUJIFILM Corporation and by research groups around the globe.
Export Options
About this article
Cite this article as:
Facchinetti Victor and de Souza Marcus Vinícius Nora*, Favipiravir in the Spotlight: In Search of Treatment Against COVID-19, Coronaviruses 2021; 2 (1) : e160223184322 . https://dx.doi.org/10.2174/2666796701999200729155347
DOI https://dx.doi.org/10.2174/2666796701999200729155347 |
Print ISSN 2666-7967 |
Publisher Name Bentham Science Publisher |
Online ISSN 2666-7975 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hybrid Viral Vectors for Vaccine and Antibody Production in Plants
Current Pharmaceutical Design Modifications of Medical Care of Chronic Liver Diseases During COVID-19 Pandemic: Necessity or Novelty?
Infectious Disorders - Drug Targets Investigation of Structural, Treatment, and Clinical Characteristics of COVID-19 Along with the Challenges Caused by its Prevalence
Infectious Disorders - Drug Targets Can Probiotics Cure Inflammatory Bowel Diseases?
Current Pharmaceutical Design The Linkage “Body Mass Index-Insomnia Levels-Eating Disorder Flexibility” in Italian Nurses During the Covid-19 Outbreak: A Psychoendocrinological Employment Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets COVID-19 Pandemic: Care for Indian Cancer Patients
Coronaviruses Coordinated Roadmap to Grip Pandemic COVID-19
Coronaviruses Does Hypofractionated Radiotherapy Regimens Increase the Vulnerability to SARS- COV-2 by Influencing ACE-2 Activity?
Coronaviruses Fungal Infections in COVID-19-Positive Patients: A Lack of Optimal Treatment Options
Current Topics in Medicinal Chemistry Coronavirus-related Disease Pandemic: A Review on Machine Learning Approaches and Treatment Trials on Diagnosed Population for Future Clinical Decision Support
Current Medical Imaging Probiotics Against Viruses; COVID-19 is a Paper Tiger: A Systematic Review
Endocrine, Metabolic & Immune Disorders - Drug Targets B Cells: Programmers of CD4 T Cell Responses
Infectious Disorders - Drug Targets Potential of Selected Indian Herbs for COVID-19
Current Traditional Medicine Nanocarriers in the Delivery of Hydroxychloroquine to the Respiratory System: An Alternative to COVID-19
Current Drug Delivery Diagnostic Value of Chest CT in Coronavirus Disease 2019 (COVID-19)
Current Medical Imaging Editorial: From Perfume Oils to Discovering and Making New Molecules: An International Chemical Biology Journey
Combinatorial Chemistry & High Throughput Screening Co-morbidity of Covid-19 and Stenotrophomonas maltophilia in a Patient with Hodgkin's Lymphoma History from North of Iran
Infectious Disorders - Drug Targets Patients with Rheumatic Diseases Overlooked during COVID-19 Pandemic: How are They Doing and Behaving?
Current Rheumatology Reviews Could Targeting HMGB1 be Useful for the Clinical Management of COVID-19 Infection?
Combinatorial Chemistry & High Throughput Screening Prognosticating the Spread of Covid-19 Pandemic Based on Optimal Arima Estimators
Endocrine, Metabolic & Immune Disorders - Drug Targets